On September 8, 2021 Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 (Press release, Moleculin, SEP 8, 2021, https://ir.moleculin.com/news/detail/225/moleculin-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference [SID1234587407]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company’s website (www.moleculin.com). The webcast replay will be archived for 90 days following the event.

On September 8, 2021 Promega Corporation reported that launched its OncoMate MSI Dx Analysis System (OncoMate MSI) in vitro diagnostic (IVD) in the US, giving oncologists and pathologists a new option to screen for Lynch syndrome in patients with colorectal cancer (Press release, Promega, SEP 8, 2021, View Source [SID1234587425]). OncoMate MSI was cleared by the US Food and Drug Administration (FDA) last month as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncoMate MSI is based on Promega technology that has been a gold standard around the world for the last 15 years for studying MSI status in solid tumors. It is the industry’s first and only PCR-based diagnostic kit for MSI characterization that is FDA-cleared for use in labs in the US.

MSI status

DNA is constantly copying itself. MSI is a form of genomic instability caused when too many or too few repeating bases, called microsatellites, occur during DNA replication and the body’s mismatch repair system fails to correct these errors. MSI status is used to screen for Lynch syndrome.

Lynch syndrome

Lynch syndrome is an inherited condition that increases the risk of developing colorectal and other cancers. It is the most common inherited cause of colorectal cancer. An estimated 1 in 279 people have Lynch syndrome but 95% do not know they have it. High-frequency MSI (MSI-H) is an indication that patients should be referred for further genetic testing for Lynch syndrome. This information is crucial not only for the patient, but for family members as well.

Promega OncoMate MSI technology

Promega OncoMate MSI is based on the company’s "for research use only" technology, the first commercially manufactured kit to detect MSI status and the leading standard test for MSI status detection in research laboratories worldwide. Promega MSI technology has been used extensively in clinical research for more than 15 years and is supported by over 140 peer-reviewed publications.

The Promega five MSI loci are often the comparative benchmark used by other companies and organizations for determining MSI status, and are referenced and recommended in guidelines by multiple societies, including the National Cancer Institute – Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) and Microsatellite Instability – and the National Comprehensive Cancer Network (NCCN).

OncoMate MSI Dx Analysis System

The FDA-cleared OncoMate MSI IVD medical device features:

Fluorescent, multiplex PCR-based fragment-sizing test
High sensitivity and specificity – targets five mononucleotide repeat markers.
Short turn-around time – from FFPE sample to answer in as little as 10 hours.
Conserves precious samples – MSI results with ≤1 FFPE section.
Promega MSI global IVD portfolio

Besides US FDA clearance, OncoMate MSI is also a CE-marked IVD medical device in the United Kingdom and select European countries. Promega intends to seek regulatory clearance for a Promega MSI IVD in China where the Promega MSI technology received innovation status and priority review by the National Medical Products Administration (NMPA).

To learn more about the OncoMate MSI Dx Analysis System, visit: www.promega.com/PromegaMSI

On September 8, 2021 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, reported that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021 (Press release, Citius Pharmaceuticals, SEP 8, 2021, https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-301369833.html [SID1234587443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation video will be available for viewing on demand starting at 7:00 am ET on Monday, September 13th. Investors may register for the conference at the event website. The archived webcast will be available for 90 days after the event and will be accessible on the Citius website.

Myron Holubiak, President and Chief Executive Officer of Citius, and Dr. Myron Czuczman, Chief Medical Officer of Citius, will discuss the Company’s expanded pipeline and near-term catalysts.

On September 8, 2021 GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, reported that Anthony Cataldo, Chairman & CEO, Dr. Greg Berk, President of R&D and Chief Medical Officer, and Dr. Jeff Miller, Consulting Chief Scientific Officer will be presenting and hosting one-on-one meetings at the upcoming H.C. Wainwright 23rd Annual Global Healthcare Conference and the Baird Global Healthcare Conference (Press release, GT Biopharma, SEP 8, 2021, View Source [SID1234587390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

H.C. Wainwright 23rd Annual Global Healthcare Conference

Date: September 13, 2021
Pre-recorded Corporate Presentation Release Time: 7:00 A.M. ET
Webcast Participation: View Source

Additionally, the management team will participate in the following live panel presentation: "Novel Therapeutic Approaches to NK Therapy in Cancer" at 1:00P.M. ET

Baird Global Healthcare Conference

Date: September 15, 2021
Time: 8:30 A.M. ET
Registration: By invitation only

If you are interested in participating in either of the conferences or to schedule a one-on-one meeting with the management team, please contact your respective representative with each conference organizer.

On September 8, 2021 Leidos (NYSE: LDOS), a FORTUNE 500 science and technology company, reported that it will participate in the Morgan Stanley Virtual 9th Annual Laguna Conference webcast (Press release, Leidos, SEP 8, 2021, View Source [SID1234587408]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chris Cage, Chief Financial Officer, will engage in a question and answer "fireside chat" on Wednesday, Sept. 15, 2021 at 2:15 p.m. ET.

A live audio webcast of the event will be available on the Leidos Investor Relations website at View Source A replay of the webcast will be available following the presentation at the same link listed above for 90 days afterward.